ArticleWorld journal of surgical oncology2025
Development of a malignancy risk prediction model combining ultrasound and cytology for Bethesda category III thyroid nodules.
Article in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The role of cytological subcategorization in indeterminate thyroid nodules: Optimizing management strategies by refining malignancy risk stratification.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026Article
- The Value of Multimodal Ultrasound in Differentiating Benign from Malignant Cytologically Indeterminate Thyroid Nodules.Cancers · 2026Article
- A malignancy risk prediction model for Bethesda category III thyroid nodules based on serological indicators, C-TIRADS, and BRAF V600E testing.Frontiers in endocrinology · 2026Article
- Preoperative risk score for malignancy in Bethesda III thyroid nodules: a multicentre retrospective study.Frontiers in endocrinology · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundBethesda category III thyroid nodules pose substantial management challenges, and a validated malignancy risk stratification system is urgently needed to guide clinical decision-making. This study aims to identify specific sonographic and cytological features associated with malignant Bethesda III thyroid nodules and to develop a practical model for predicting malignancy risk through an integrated analysis of multimodal data from histopathologically confirmed cases.
methodsThis retrospective study used clinical data from patients with both Bethesda III cytological diagnoses and corresponding surgical pathology outcomes between July 2016 and December 2024. The sonographic, clinical, and cytological characteristics of benign and malignant nodules were systematically assessed and compared. Univariable and multivariable logistic regression analyses were conducted to evaluate the association between these features and malignancy. A prediction nomogram, incorporating sonographic and cytological features independently associated with malignancy, was developed and validated to assess its performance.
resultsIn this study, a total of 187 Bethesda III thyroid nodules were analyzed, consisting of 77 benign nodules and 110 malignant nodules. Factors such as maximum diameter ≤ 1 cm, absence of smooth margins, microcalcifications, and nuclear atypia in cytology were identified as independent factors associated with malignancy. A prediction nomogram model was developed using these variables, demonstrating strong performance in distinguishing between benign and malignant nodules categorized as Bethesda III, with an area under the curve (AUC) of 0.874.
conclusionsIn Bethesda III thyroid nodules, malignant cases were associated with suspicious sonographic characteristics, smaller size (≤ 1 cm), and cytological nuclear atypia. The nomogram developed from these predictors demonstrates potential utility in estimating malignancy risk for Bethesda III thyroid nodules.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.